CR9775A - Moduladores de teramuteina - Google Patents

Moduladores de teramuteina

Info

Publication number
CR9775A
CR9775A CR9775A CR9775A CR9775A CR 9775 A CR9775 A CR 9775A CR 9775 A CR9775 A CR 9775A CR 9775 A CR9775 A CR 9775A CR 9775 A CR9775 A CR 9775A
Authority
CR
Costa Rica
Prior art keywords
theramuteine
modulators
activators
inhibitors
agents
Prior art date
Application number
CR9775A
Other languages
English (en)
Inventor
Gerard M Housey
Original Assignee
Gerard M Housey
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gerard M Housey filed Critical Gerard M Housey
Publication of CR9775A publication Critical patent/CR9775A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/76—Nitrogen atoms to which a second hetero atom is attached
    • C07D213/77—Hydrazine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
    • C07D253/06—1,2,4-Triazines
    • C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
    • C07D253/07—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Esta invencion se relaciona con agentes que son inhibidores o activadores de formas variantes de proteinas endogenas y con metodos novedosos de identificar esas variantes.
CR9775A 2005-08-29 2008-02-29 Moduladores de teramuteina CR9775A (es)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US71274205P 2005-08-29 2005-08-29
US71551705P 2005-09-09 2005-09-09
US73947705P 2005-11-23 2005-11-23
US73947605P 2005-11-23 2005-11-23
US74176705P 2005-12-02 2005-12-02
US75103005P 2005-12-16 2005-12-16
US78310606P 2006-03-13 2006-03-13
US78581706P 2006-03-23 2006-03-23
US78590406P 2006-03-23 2006-03-23
US78937906P 2006-04-04 2006-04-04

Publications (1)

Publication Number Publication Date
CR9775A true CR9775A (es) 2010-01-15

Family

ID=37900213

Family Applications (1)

Application Number Title Priority Date Filing Date
CR9775A CR9775A (es) 2005-08-29 2008-02-29 Moduladores de teramuteina

Country Status (10)

Country Link
US (1) US20100016298A1 (es)
EP (1) EP1928847A4 (es)
JP (1) JP2009506125A (es)
KR (1) KR20080090381A (es)
AU (1) AU2006295260A1 (es)
CA (1) CA2620878A1 (es)
CR (1) CR9775A (es)
IL (1) IL189846A0 (es)
NZ (1) NZ566744A (es)
WO (1) WO2007037898A2 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ564222A (en) * 2005-06-14 2011-10-28 Taigen Biotechnology Co Ltd Pyrimidine compounds
US8193206B2 (en) 2005-06-14 2012-06-05 Taigen Biotechnology Co., Ltd. Pyrimidine compounds
CN103789389B (zh) * 2005-11-23 2017-01-04 杰勒德·M·豪斯 鉴定、合成、优化和表征蛋白调节剂的化合物和方法
EP2121681B1 (en) 2007-01-11 2015-04-15 Critical Outcome Technologies, Inc. Compounds and method for treatment of cancer
CA2710039C (en) 2007-12-26 2018-07-03 Critical Outcome Technologies, Inc. Semicarbazones, thiosemicarbazones and related compounds and methods for treatment of cancer
DK2268635T3 (en) 2008-04-21 2015-09-14 Taigen Biotechnology Co Ltd Heterocyclic Compounds
EP2318406B1 (en) 2008-07-17 2016-01-27 Critical Outcome Technologies, Inc. Thiosemicarbazone inhibitor compounds and cancer treatment methods
EP2552915B1 (en) 2010-04-01 2017-07-19 Critical Outcome Technologies Inc. Compounds for the treatment of hiv
JP5822840B2 (ja) * 2010-09-30 2015-11-24 ダイトーケミックス株式会社 眼疾患処置薬
US10012118B2 (en) * 2013-01-31 2018-07-03 Filtran Llc Filter with dual pleat pack
JP6217999B2 (ja) * 2014-10-09 2017-10-25 Dic株式会社 重合性化合物及び光学異方体
US11046889B2 (en) 2015-12-08 2021-06-29 Dic Corporation Polymerizable compound and optically anisotropic body
EP3795563B1 (en) 2016-03-31 2024-07-17 Oncternal Therapeutics, Inc. Indoline analogs and uses thereof
US20220027795A1 (en) * 2020-07-27 2022-01-27 Recursion Pharmaceuticals, Inc. Techniques for training a classifier to detect executional artifacts in microwell plates

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2327096A1 (de) * 1973-05-28 1974-12-19 Henkel & Cie Gmbh Entzuendungshemmer fuer kosmetische praeparationen
GB8829296D0 (en) * 1988-12-15 1989-01-25 Ici Plc Anti-tumour compounds
DE19603576A1 (de) * 1996-02-01 1997-08-07 Bayer Ag Acylierte 4-Amino und 4-Hydrazinopyrimidine
GB9615832D0 (en) * 1996-07-27 1996-09-11 Agrevo Uk Ltd Fungicides
SK7692001A3 (en) * 1998-12-09 2002-09-10 Wyeth Corp Thiourea inhibitors of herpes viruses
WO2001012189A1 (en) * 1999-08-12 2001-02-22 Pharmacia Italia S.P.A. 3(5)-amino-pyrazole derivatives, process for their preparation and their use as antitumor agents
DOP2000000109A (es) * 1999-12-23 2002-08-30 Gerald Kleymann Derivados de tiazolilamida
US6770666B2 (en) * 1999-12-27 2004-08-03 Japan Tobacco Inc. Fused-ring compounds and use thereof as drugs
JP2001247550A (ja) * 1999-12-27 2001-09-11 Japan Tobacco Inc 縮合環化合物及びその医薬用途
JP2002145840A (ja) * 2000-01-25 2002-05-22 Japan Tobacco Inc Ｎ−アリールヒドラジド化合物及びその医薬用途
AU2001265656A1 (en) * 2000-06-05 2001-12-17 Johnny Easmon Heterocyclic hydrazones for use as anti-cancer agents
US6290929B1 (en) * 2000-07-28 2001-09-18 The Procter & Gamble Company Cancer treatment
DE10148618B4 (de) * 2001-09-25 2007-05-03 Schering Ag Substituierte N-(1,4,5,6-Tetrahydro-cyclopentapyrazol-3-yl)-Derivate, deren Herstellung und Verwendung als Arzneimittel
MXPA05001277A (es) * 2002-08-02 2005-10-06 Ab Science 2-(3-aminoaril)amino-4-aril-tiazoles y su uso como inhibidores del c-kit.
RU2337908C2 (ru) * 2003-06-12 2008-11-10 Ново Нордиск А/С Пиридинилкарбаматы в качестве ингибиторов гормон-чувствительной липазы
EP1684762A4 (en) * 2003-11-13 2009-06-17 Ambit Biosciences Corp UREA DERIVATIVES AS MODULATORS OF KINASE
AU2005219788B2 (en) * 2004-03-05 2010-06-03 Nissan Chemical Corporation Isoxazoline-substituted benzamide compound and noxious organism control agent
EP3461813A1 (en) * 2004-05-23 2019-04-03 Gerard M. Housey Theramutein modulators

Also Published As

Publication number Publication date
KR20080090381A (ko) 2008-10-08
JP2009506125A (ja) 2009-02-12
WO2007037898A3 (en) 2007-06-07
WO2007037898A8 (en) 2008-11-06
US20100016298A1 (en) 2010-01-21
WO2007037898A2 (en) 2007-04-05
EP1928847A4 (en) 2011-08-10
EP1928847A2 (en) 2008-06-11
CA2620878A1 (en) 2007-04-05
NZ566744A (en) 2011-04-29
AU2006295260A1 (en) 2007-04-05
IL189846A0 (en) 2008-08-07

Similar Documents

Publication Publication Date Title
CR9775A (es) Moduladores de teramuteina
CY1124802T1 (el) Δεσμευτικοι παραγοντες σκληροστινης
ECSP088543A (es) Anticuerpos anti-ox40l y métodos que los utilizan
EA201001860A1 (ru) Ингибиторы дпп-4 для лечения неалкогольной жировой дистрофии печени
CR20120421A (es) Compuestos de aminohetetoarilo o sustituidos con pirazol como inhibidores de proteina quinasa
CY1109741T1 (el) Sns-595 και μεθοδοι χρησης αυτου
ECSP099027A (es) Anticuerpos anti-dll4 y métodos que los usan
MX338884B (es) Composiciones y metodos que comprenden variantes de proteasa.
DE602005019971D1 (de) Inhibitoren von cysteinprotease
CR8888A (es) Indazoles utiles en el tratamiento de enfermedades cardiovasculares
SV2011003834A (es) Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c5
EA201270553A1 (ru) Ингибиторы тирозинкиназы брутона
MX373170B (es) Variantes de la familia il-1.
CR11139A (es) Anticuerpos anti-notch1 nrr y sus metodos de uso
DE502007002289D1 (de) Methacrylatharze zur herstellung von fahrbahnmarkierungen
NO20071127L (no) Triazoloftalaziner
ECSP088743A (es) Anticuerpos para egfl7 y métodos para su uso
EP1817276A4 (en) CATHEPSINCYSTEINPROTEASEHEMMER
AR059096A1 (es) Anticuerpos anti- efrina -b2 y metodos que usan estos
PA8667201A1 (es) Nuevos compuestos farmaceuticos
AR063765A1 (es) Composiciones y metodos para promover la adhesion entre un sustrato y un recubrimiento de poliurea/poliuretano
EA200701528A1 (ru) Новые нутрицевтические композиции
SV2006002001A (es) Inhibidores de quinasa ref. x - 16437
CR8545A (es) Piperidinilcarbonil-pirrolidinas y su empleo comoagonistas de melanocortina
EA200601743A1 (ru) Выделенный полипептид реналазы и его применение

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)